DBV Technologies S.A. (DBVT) |
|
1.3225 -0.048 (-3.47%)
|
09-26 14:36 |
|
Open: |
1.29 |
Pre. Close: |
1.37 |
|
High:
|
1.38 |
Low:
|
1.29 |
|
Volume:
|
75,635 |
Market Cap:
|
267(M) |
|
|
|
Technical analysis |
as of: 2023-09-26 2:48:24 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
|
| Target: |
Six months: 1.91  One year: 2.16 |
| Support: |
Support1: 1.28 Support2: 1.07 |
| Resistance: |
Resistance1: 1.63 Resistance2: 1.85 |
| Pivot: |
1.47 |
| Moving Average: |
MA(5): 1.4 MA(20): 1.51
MA(100): 1.71 MA(250): 1.58 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 9 %D(3): 12.3 |
| RSI: |
RSI(14): 34.4 |
| 52-week: |
High: 2.36 Low: 1.08 |
| Average Vol(K): |
3-Month: 125 (K) 10-Days: 79 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ DBVT ] has closed above bottom band by 5.0%. Bollinger Bands are 2.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.41 - 1.42 |
1.42 - 1.43 |
|
Low:
|
1.3 - 1.31 |
1.31 - 1.32 |
|
Close:
|
1.34 - 1.35 |
1.35 - 1.36 |
|
Company Description |
|
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France. |
Headline News |
Thu, 14 Sep 2023
Premarket Mover: DBV Technologies SA - ADR (DBVT) Up 0.66% - InvestorsObserver
Tue, 05 Sep 2023
DBV Technologies invitée à participer à une prochaine Conférence ... - Zonebourse.com
Mon, 31 Jul 2023
DBV Technologies Receives Feedback from FDA on Design ... - GlobeNewswire
Wed, 10 May 2023
DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers - Yahoo Finance
Wed, 19 Apr 2023
DBV Technologies Outlines Regulatory Path for Viaskin Peanut in ... - GlobeNewswire
Tue, 07 Mar 2023
DBV Technologies Announces First Patient Screened in VITESSE ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
192 (M) |
|
% Held by Insiders
|
6.689e+007 (%) |
|
% Held by Institutions
|
0.2 (%) |
|
Shares Short
|
1,160 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-9e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
947.4 |
|
Return on Equity (ttm)
|
-25.5 |
|
Qtrly Rev. Growth
|
5.25e+006 |
|
Gross Profit (p.s.)
|
42.39 |
|
Sales Per Share
|
-42.39 |
|
EBITDA (p.s.)
|
4.13675e+006 |
|
Qtrly Earnings Growth
|
-0.6 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-90 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.04 |
|
Price to Cash Flow
|
1.82 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.18e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
